175 related articles for article (PubMed ID: 30019101)
1. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.
Wang E; Xia D; Bai W; Wang Z; Wang Q; Liu L; Wang W; Yuan J; Li X; Chen H; Lv Y; Niu J; He C; Guo W; Yin Z; Luo B; Han N; Wang Z; Yu T; Yuan X; Li K; Tie J; Li C; Cai H; Xia J; Fan D; Han G
Invest New Drugs; 2019 Jun; 37(3):401-414. PubMed ID: 30019101
[TBL] [Abstract][Full Text] [Related]
2. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
3. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
4. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract][Full Text] [Related]
5. Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma.
Wang E; Xia D; Bai W; Yuan J; Li X; Niu J; Yin Z; Xia J; Cai H; Fan D; Han G; Liu L
BMC Cancer; 2019 Apr; 19(1):409. PubMed ID: 31039750
[TBL] [Abstract][Full Text] [Related]
6. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
Lamarca A; Abdel-Rahman O; Salu I; McNamara MG; Valle JW; Hubner RA
Clin Transl Oncol; 2017 Mar; 19(3):364-372. PubMed ID: 27541594
[TBL] [Abstract][Full Text] [Related]
7. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
8. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
13. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma.
Naganuma A; Hoshino T; Ohno N; Ogawa Y; Murakami T; Horiguchi S; Uehara D; Suzuki Y; Hatanaka T; Kudo T; Ishihara H; Sato K; Kakizaki S; Takagi H
In Vivo; 2019; 33(1):155-161. PubMed ID: 30587616
[TBL] [Abstract][Full Text] [Related]
14. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Howell J; Pinato DJ; Ramaswami R; Bettinger D; Arizumi T; Ferrari C; Yen C; Gibbin A; Burlone ME; Guaschino G; Sellers L; Black J; Pirisi M; Kudo M; Thimme R; Park JW; Sharma R
Aliment Pharmacol Ther; 2017 Apr; 45(8):1146-1155. PubMed ID: 28252185
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
16. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib.
Liu L; Wang E; Li L; Chen D; Peng K; Wang M; Han G
Can J Gastroenterol Hepatol; 2019; 2019():2576349. PubMed ID: 31815114
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Díaz-González Á; Sanduzzi-Zamparelli M; Sapena V; Torres F; LLarch N; Iserte G; Forner A; da Fonseca L; Ríos J; Bruix J; Reig M
Aliment Pharmacol Ther; 2019 Mar; 49(5):482-491. PubMed ID: 30695819
[TBL] [Abstract][Full Text] [Related]
18. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.
Tovoli F; Ielasi L; Casadei-Gardini A; Granito A; Foschi FG; Rovesti G; Negrini G; Orsi G; Renzulli M; Piscaglia F
J Hepatol; 2019 Dec; 71(6):1175-1183. PubMed ID: 31449860
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
Imedio ER; Beveridge RD; Urtasun JA; Campos GB; Estellés DL; Esparcia MF; Daroqui JC; Huerta ÁS; Ortiz AG; Salcedo JM
Med Oncol; 2014 May; 31(5):948. PubMed ID: 24740650
[TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]